查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1697365

委外研发机构(CRO) 服务市场 - 2025 年至 2030 年预测

Contract Research Organizations (CRO) Services Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2025 年全球委外研发机构(CRO) 服务市场价值估计为 1,204.87 亿美元，预计到 2030 年将达到 1,753.45 亿美元，复合年增长率为 7.79%。

由于对临床试验和研究活动外包服务的需求不断增加，全球合约研究组织市场正在经历强劲成长。市场正在整合许多新兴技术，例如人工智慧、资料分析和区块链技术。主要市场参与者正在建立策略联盟，以扩大其提供 CRO 服务的能力。

市场趋势：

  • 全球慢性疾病患者数量增加：慢性病（尤其是癌症和糖尿病）的盛行率不断上升，是推动合约委外研发机构(CRO) 服务需求的关键因素。慢性疾病患者数量的增加使得药物研发变得特别迫切，也增加了对高效临床试验服务的需求。
  • 增加研发投入：市场主要参与者正在增加研发投入，促进 CRO 市场的发展。
  • 2024年11月，Astra Zeneca宣布将在美国投资约35亿美元用于新药研发和製造。
  • 透过结合智慧和资料分析等技术，研究能力进一步增强。
  • 北美市场动态：
  • 北美引领 CRO 服务市场，主要原因是：
  • 先进的医疗保健基础设施
  • 融合人工智慧、区块链等创新技术
  • 2023 年 1 月，知名监管和品质咨询公司 RQM+ 扩大了其产品范围，推出了全面的临床试验服务。
  • 亚太地区的成长潜力：
  • 印度、中国和韩国等亚太地区的经济快速成长，大大加强了其医疗保健基础设施。
  • 拥有成本效益高且技术熟练的劳动力是这些国家 CRO 服务成长的关键因素。
  • 结论：全球慢性病发病率的上升和研发投入的增加正在塑造委外研发机构的格局。随着药物开发和临床试验服务需求的不断增长，北美和亚太地区被定位为推动市场扩张的关键地区。

报告中介绍的主要企业包括 PPD Inc（赛默飞世尔科技公司）、IQVIA Inc、ICON plc、Paraxel International Corporation、NAMSA、Labcorp Drug Development、无锡药明康德、Syneos Health、Evotec SE、Novotech、CliniExperts、PharPoint 和 Veranex。

本报告的主要优点

  • 深刻分析：获得涵盖主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响市场的未来发展。
  • 可行的建议：利用洞察力进行策略决策，在动态环境中开闢新的业务流和收益。
  • 使用者范围广泛：对新兴企业、研究机构、顾问、中小企业和大型企业都有利且具有成本效益

它有什么用途？

产业和市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2024 年的历史资料和 2025 年至 2030 年的预测资料
  • 成长机会、挑战、供应链前景、法规结构、趋势分析
  • 竞争市场条件、策略与市场占有率分析
  • 对各细分市场和地区（包括国家）的收益成长和预测评估
  • 公司简介（策略、产品、财务资讯、主要发展等）

全球合约研究组织市场分析为以下几个部分：

依分子类型

  • 疫苗
  • 细胞和基因治疗
  • 其他的

按类型

  • 早期开发服务
  • 临床研究服务
  • 化验服务
  • 咨询服务

按治疗领域

  • 肿瘤学
  • 中枢神经系统疾病
  • 其他治疗领域

按最终用途

  • 製药和生物製药公司
  • 医疗设备公司
  • 学术机构

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 英国
  • 德国
  • 法国
  • 西班牙
  • 其他的
  • 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
  • 亚太地区
  • 中国
  • 日本
  • 印度
  • 韩国
  • 台湾
  • 其他的

目录

第一章 引言

  • 市场概览
  • 市场定义
  • 研究范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 研究过程

第三章执行摘要

  • 主要发现
  • CXO观点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

5. 合约研究组织 (CRO) 服务市场（按分子类型）

  • 介绍
  • 疫苗
  • 细胞和基因治疗
  • 其他的

6.委外研发机构(CRO) 服务市场（按类型）

  • 介绍
  • 早期开发服务
    • 临床前
    • 毒性测试
    • 发现研究
    • 化学、製造和控制
    • 药物动力学/动态
  • 临床研究服务
    • 第一阶段
    • 第二阶段
    • 第三阶段
    • 第四阶段
    • 第五阶段
  • 化验服务

6.4.1.分析测试

    • 生物分析测试
    • 物理特性
    • 稳定性测试、批次放行测试
    • 原料检测
    • 其他分析测试
  • 咨询服务

7.委外研发机构(CRO) 服务市场（按治疗领域）

  • 介绍
  • 肿瘤学
    • 乳癌
    • 肺癌
    • 大肠直肠癌
    • 摄护腺癌
    • 其他的
  • 中枢神经系统疾病
    • 感染疾病
    • 心血管疾病
    • 呼吸系统疾病
    • 糖尿病
  • 其他治疗领域

8.委外研发机构(CRO) 服务市场（依最终用途）

  • 介绍
  • 製药和生物製药公司
  • 医疗设备公司
  • 学术机构

9.委外研发机构(CRO) 服务市场（按地区）

  • 介绍
  • 北美洲
    • 依分子类型
    • 按类型
    • 按治疗领域
    • 按最终用途
    • 按国家
  • 南美洲
    • 依分子类型
    • 按类型
    • 按治疗领域
    • 按最终用途
    • 按国家
  • 欧洲
    • 依分子类型
    • 按类型
    • 按治疗领域
    • 按最终用途
    • 按国家
  • 中东和非洲
    • 依分子类型
    • 按类型
    • 按治疗领域
    • 按最终用途
    • 按国家
  • 亚太地区
    • 依分子类型
    • 按类型
    • 按治疗领域
    • 按最终用途
    • 按国家

第十章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争仪錶板

第十一章 公司简介

  • PPD Inc.（Thermo Fisher Scientific Inc）
  • IQVIA Inc
  • ICON Plc
  • Parexel International Corporation
  • NAMSA
  • Labcorp Drug Development
  • WuXi AppTec
  • Syneos Health
  • Evotec SE
  • Novotech
  • CliniExperts
  • PharPoint
  • Veranex
简介目录
Product Code: KSI061615663

The global contract research organization (CRO) service market was estimated at US$ 120.487 billion in 2025 and is expected to grow at a CAGR of 7.79% to attain US$ 175.345 billion by 2030.

The Global Contract Research Organizations Market is experiencing robust growth due to increasing demand for outsourcing services of clinical trials and research activities. The market witnessing the integration of many new emerging technologies such as artificial intelligence, data analytics, and blockchain technology among others. There are strategic collaborations by key market players to expand their capabilities in offering CRO services.

Market Trends:

  • Rise in Global Cases of Chronic Diseases: The increasing prevalence of chronic diseases, particularly cancers and diabetes, is a significant factor driving the demand for contract research organization (CRO) services. The growth in chronic disease cases necessitates enhanced drug development efforts, leading to a heightened need for efficient clinical trial services.
  • Growing Investment in Research and Development: Key market players are increasing their investments in research and technology, contributing to advancements in the CRO market. Notable examples include:
  • In November 2024, AstraZeneca announced an investment of approximately $3.5 billion for research and development, as well as manufacturing new drugs in the USA.
  • The incorporation of technologies such as artificial intelligence and data analytics is further enhancing research capabilities.
  • North America Market Dynamics:
  • North America leads the CRO services market, driven by:
  • An advanced healthcare infrastructure.
  • The integration of innovative technologies such as artificial intelligence and blockchain.
  • In January 2023, RQM+, a prominent regulatory and quality consulting firm, expanded its offerings by introducing comprehensive clinical trial services.
  • Asia-Pacific Growth Potential:
  • Rapidly growing economies in the Asia-Pacific region, including India, China, and South Korea, are significantly enhancing healthcare infrastructure.
  • The availability of a cost-effective and skilled workforce is a critical factor contributing to the growth of CRO services in these countries.
  • Conclusion: The rising global incidence of chronic diseases and increasing investments in research and development are shaping the landscape for contract research organizations. As the demand for drug development and clinical trial services continues to grow, both North America and Asia-Pacific are positioned as key regions driving this market's expansion.

Some of the major players covered in this report include PPD Inc. (Thermo Fisher Scientific Inc.), IQVIA Inc, ICON plc, Paraxel International Corporation, NAMSA, Labcorp Drug Development, WuXi AppTec, Syneos Health, Evotec SE, Novotech, CliniExperts, PharPoint, Veranex among others.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Global Contract Research Organizations Market is analyzed into the following segments:

By Molecular Type

  • Vaccines
  • Cell Gene Therapy
  • Others

By Type

  • Early Phase Development Services
  • Clinical Research Services
  • Laboratory Services
  • Consulting Services

By Therapeutic Area

  • Oncology
  • CNS Disorders
  • Other Therapeutic Areas

By End-User

  • Pharmaceuticals and Biopharmaceuticals Companies
  • Medical Devices Companies
  • Academic Institutes

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. CONTRACT RESEARCH ORGANIZATIONS MARKET (CRO) SERVICES BY MOLECULAR TYPE

  • 5.1. Introduction
  • 5.2. Vaccines
  • 5.3. Cell Gene Therapy
  • 5.4. Others

6. CONTRACT RESEARCH ORGANIZATIONS (CRO) SERVICES MARKET BY TYPE

  • 6.1. Introduction
  • 6.2. Early Phase Development Services
    • 6.2.1. Preclinical
    • 6.2.2. Toxicology Testing
    • 6.2.3. Discovery Studies
    • 6.2.4. Chemistry, Manufacturing, and Controls
    • 6.2.5. Pharmacokinetics /Pharmacodynamics
  • 6.3. Clinical Research Services
    • 6.3.1. Phase I
    • 6.3.2. Phase II
    • 6.3.3. Phase III
    • 6.3.4. Phase IV
    • 6.3.5. Phase V
  • 6.4. Laboratory Services

6.4.1. Analytical Testing

    • 6.4.2. Bioanalytical Testing
    • 6.4.3. Physical Characterization
    • 6.4.4. Stability Testing, Batch Release Testing
    • 6.4.5. Raw Material Testing
    • 6.4.6. Other Analytical Testing
  • 6.5. Consulting Services

7. CONTRACT RESEARCH ORGANIZATIONS (CRO) SERVICES MARKET BY THERAPEUTIC AREA

  • 7.1. Introduction
  • 7.2. Oncology
    • 7.2.1. Breast Cancer
    • 7.2.2. Lung Cancer
    • 7.2.3. Colorectal Cancer
    • 7.2.4. Prostate Cancer
    • 7.2.5. Others
  • 7.3. CNS Disorders
    • 7.3.1. Infectious Diseases
    • 7.3.2. Cardiovascular Diseases
    • 7.3.3. Respiratory Disorders
    • 7.3.4. Diabetes
  • 7.4. Other Therapeutic Areas

8. CONTRACT RESEARCH ORGANIZATIONS (CRO) SERVICES MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Pharmaceuticals and Biopharmaceuticals Companies
  • 8.3. Medical Devices Companies
  • 8.4. Academic Institutes

9. CONTRACT RESEARCH ORGANIZATIONS (CRO) SERVICES MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Molecular Type
    • 9.2.2. By Type
    • 9.2.3. By Therapeutic Area
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. USA
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. By Molecular Type
    • 9.3.2. By Type
    • 9.3.3. By Therapeutic Area
    • 9.3.4. By End-User
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Others
  • 9.4. Europe
    • 9.4.1. By Molecular Type
    • 9.4.2. By Type
    • 9.4.3. By Therapeutic Area
    • 9.4.4. By End-User
    • 9.4.5. By Country
      • 9.4.5.1. United Kingdom
      • 9.4.5.2. Germany
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. By Molecular Type
    • 9.5.2. By Type
    • 9.5.3. By Therapeutic Area
    • 9.5.4. By End-User
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
      • 9.5.5.2. UAE
      • 9.5.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. By Molecular Type
    • 9.6.2. By Type
    • 9.6.3. By Therapeutic Area
    • 9.6.4. By End-User
    • 9.6.5. By Country
      • 9.6.5.1. China
      • 9.6.5.2. Japan
      • 9.6.5.3. South Korea
      • 9.6.5.4. Australia
      • 9.6.5.5. India
      • 9.6.5.6. Indonesia
      • 9.6.5.7. Thailand
      • 9.6.5.8. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. PPD Inc. (Thermo Fisher Scientific Inc)
  • 11.2. IQVIA Inc
  • 11.3. ICON Plc
  • 11.4. Parexel International Corporation
  • 11.5. NAMSA
  • 11.6. Labcorp Drug Development
  • 11.7. WuXi AppTec
  • 11.8. Syneos Health
  • 11.9. Evotec SE
  • 11.10. Novotech
  • 11.11. CliniExperts
  • 11.12. PharPoint
  • 11.13. Veranex